The Preprint highlights the dire need to have an effective

New Post Public Reply Private Reply Replies (3) Message Board
Mo farrell #66281
992
The Preprint highlights the dire need to have an effective therapeutic to treat CV19. The Pandemic is not going away anytime soon and many countries are currently seeing record cases. Vaccines and therapeutics are needed weapons to combat CV19.

There are multiple vaccine offerings in development and we will probably see at least one of these offerings for CV19 sometime in 2021. There are always questions regarding effectiveness, short term safety and long term impacts to consider. IF these issues are all addressed there is still at least half of the population that will choose to avoid vaccination. If you use optimistic safety projections and believe a vaccine developer could hit a 50% effectiveness threshold, it would equate to 75% of the population that would still be at risk. Therapeutics will be needed for the foreseeable future for CV19 and there is an ongoing need to treat a plethora of other viruses and potential future pandemics.

There are multiple strategies that are being used for CV19 therapeutics. One of the major strategies is to develop synthetic or artificial antibodies to fight the virus. Two of the major players in this market are Regeneron and Eli Lilly, both of whom have had major safety issues in their perspective human trials. The latest Regeneron efficacy results with their REGN-COV2 cocktail reduced medical visits by 57% by day 29. The efficacy profile for antibody treatments appears to have the greatest impact early in the disease and less so as the disease progresses. IMO Brilacidin has a huge advantage from a safety perspective over these antibody cocktail approaches and should also blow away these approaches from an efficacy perspective if the outstanding Brilacidin RBL lab results carry forward into human trials.

The other major group of CV19 therapeutics are classic antiviral treatments. Most of these offerings are repurposed drugs that were originally developed for other viruses and have very mixed results for treating CV19. The common theme with these repurposed antivirals is that they are also more effective in the very early stages of disease exposure to limit viral replication. As the disease progresses these antivirals become less effective in treating the disease as most do not have a virucidal mechanism of action design.

The lead antiviral to treat CV19 is Gilead’s Remdesivir drug. Hangout post #66978 has an article that discusses what I consider the current low bar set by Remdesivir as a CV19 treatment.

The following is from farrell’s post # 66281
“Brilacidin's triple MOAs are unparalleled. Remdesivir prevents viral replication. Regeneron's monoclonal antibodies prevents viral cell wall penetration. Brilacidin prevents viral replication,viral penetration into the cell plus destroys the virus by opening the viral outer coating .
The opening of the viral coat allows Brilacidin to quickly kill the virus before it enters the cell. This virucidal MOA should allow Brilacidin to quickly lower the viral load which is likely to reduce morbidity and mortality. The 3 MOA's make resistance and the development of resistant mutations less likely.”

Read More: https://investorshangout.com/post/view?id=588...z6chq1Bz4U


Brilacidin has a much stronger safety and overall efficacy profile and should prove to be a superior stand-alone treatment in comparison to Remdesivir as a CV19 treatment. The Preprint highlights that Brilacidin also has unique synergistic capabilities that elevate Brilacidin from a 90% effectiveness in viral reduction to near 100% when combined with Remdesivir. These 2 drugs actually have complimentary mechanisms of action and when combined become a more effective treatment than either of them are individually as stand-alone treatments.

If you were the Gilead CEO and had an approved drug that was worth billions in addressing a worldwide pandemic, what would you do if you became aware of a superior competitive offering that could actually make your lead drug drastically more effective? If I was in this position I would look at one of 3 approaches; buy it, bury it or partner with it. With the Preprint available, IND approval and human trails being initiated in the next few weeks the “bury it” option is too late. That leaves the 2 options of “buy it” or “partner with it”. My guess is that we will soon see a 2nd B-CV19 human trial as a combination trial with Remdesivir. Gilead needs IPIX more than IPIX needs Gilead IMO. If this trial does indeed take place, my guess is that it would be at little to no expense to IPIX. If a combo human trial matched the near 100% lab success we could potentially see a competitive drug called Remdesivir Plus that will sell for a very high premium and IPIX would get a windfall of revenue as the “Plus” is where the secret sauce has a majority of the benefit.

Now put your Leo CEO hat on for a moment. You have weathered criminal attacks on your company for years that have slowed down your mission of science advancement and shareholder maximization. (Look at 4kids post # 67073 for how the criminals are desperately attempting to continue the compression of IPIX SP). You own what appears to soon be the Gold Standard treatment for a worldwide pandemic. Success in B-CV19 Human Trials will confirm Brilacidin as a new class treatment that will generate billions as a franchise drug for treating many diseases and create huge shareholder wealth. If I were in Leo’s shoes I would personally keep my options open but stay focused on getting the B-CV19 trials successfully completed knowing that my hand is finally and increasingly becoming very strong and that I will very soon be negotiating from a position of absolute strength. There are many options of how this could unfold. The bashers continue to criticize my sticky post # 65303 where I lay out a case for the long term value proposition of Brilacidin. If you notice they have not refuted any of my assumptions in that post as part of the foundation for the value of Brilacidin. What they attack is the actual share price (SP) result of those assumptions. That is the last thing that the criminals can build their false narratives around as SP is the last thing they can control. Soon the criminals will lose control of SP which will happen increasingly with each IPIX milestone met.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Texas Plumbing Award Signals Local Service Discipline

Updated Category News Views 67

A clogged main line is not glamorous, but it is where a local service reputation gets tested for real. Neighborhood Plumbing and Drain has been named a 2026 Best of Texas Award winner in the Plumbing Contractors category, a recognition that matters less as a trophy than as a public signal: customers around Central Texas have noticed the outfit. For anyone watching the...

Continue Reading
NextPlat’s 150-Patient Test Has a Long Road Ahead

Updated Category News Views 114

A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...

Continue Reading
Eight O'Clock Adds Blonde Roast Pods to Its Lineup

Updated Category News Views 149

A lighter cup of coffee just became Eight O'Clock Coffee's newest swing at the single-serve shelf. On Nov. 19, 2026, the company said it introduced Blonde Roast K-Cup pods, a bright and smooth option aimed at drinkers who prefer a lighter roast. The product is available through Keurig.com and Amazon. That is the whole announcement, and frankly it is better to keep it that...

Continue Reading
StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 111

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
HLRBO's Data-Heavy Rebuild Changes Hunting Lease Market

Updated Category News Views 149

A hunting lease used to begin with hearsay, blurry photos, and a whole lot of hoping. HLRBO is trying to drag that stubbornly analog process into a data-rich, phone-first marketplace, and frankly, it is about time. The company rebuilt its web and mobile platforms around parcel information, plain-language AI search, mobile lease completion, and its Land IQ™ scoring...

Continue Reading
PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 110

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 156

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 76

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
Stowers Brings a Transformation CTO Into Its Lab

Updated Category News Views 31

Data Has Become Lab Infrastructure Microscopes may get the glory, but the plumbing behind modern biology is increasingly digital, sprawling and unforgiving. That is why Stowers Institute for Medical Research appointing Brandon Mayer as vice president and chief technology officer on November 19, 2026, deserves more attention than the usual executive-shuffle treatment. This...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 190

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading

Top 5 Most Recently Viewed Articles

Hexagon Agility Nets Record $100M Order from Certarus

Updated Category News Views 79

Hexagon Agility and Certarus: A Major Deal Secured There ain't nothing like landing a big fish in the business world, and Hexagon Agility just hooked a whopper. This major player in clean fuel solutions secured an order from Certarus worth a hefty $100 million. For those who keep tabs, that's Hexagon's largest order for Mobile Pipeline® modules to date, and it's all...

Continue Reading
Performance Food Group Co's Earnings: What to Expect

Updated Category News Views 111

Preparing for Performance Food Group Co's Earnings Report Performance Food Group Co PFGC is on the verge of releasing its latest quarterly earnings report. Investors are keen to know what to anticipate ahead of this significant announcement. Expectations for Earnings Performance Analysts anticipate that Performance Food Group Co will report an earnings per share (EPS) of...

Continue Reading
Innovative Collaboration Transforms Healthcare for Incarcerated Patients

Updated Category News Views 360

Innovative Partnership Shaping Correctional Healthcare Armor Health is embarking on a transformative journey in correctional healthcare through an exciting partnership with Antidote-AI, set to significantly enhance the services provided to incarcerated individuals. This collaboration brings advanced artificial intelligence (AI) capabilities to the forefront of a critical...

Continue Reading
Celebrating Innovation: A Journey Through 17 Years of Left Field Labs

Updated Category News Views 405

Left Field Labs Marks 17 Years of Innovation and Growth Left Field Labs, a creative technology agency within Stagwell (NASDAQ: STGW), celebrates its 17th anniversary with impressive revenue growth and a diverse global client base. This celebration highlights its commitment to delivering transformative digital experiences using advanced AI technologies. Transformative...

Continue Reading
Leadership Changes at Humphreys Capital Pave New Pathway

Updated Category News Views 465

Humphreys Capital's Leadership Transition Overview Humphreys Capital, a prominent institutional investment manager, has announced significant changes in its leadership team. This transition includes the appointment of Grant Humphreys as Chairman of the Board of Directors, succeeding his father, Kirk Humphreys, who will continue his involvement as Chairman Emeritus. Blair...

Continue Reading